Oramed Pharmaceuticals (ORMP) Profit After Tax (2011 - 2026)

Oramed Pharmaceuticals (ORMP) has 15 years of Profit After Tax data on file, last reported at $38.3 million in Q1 2026.

• Quarterly Profit After Tax rose 601.31% year-over-year to $38.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $129.3 million (up 557.65% YoY) and the FY2025 annual result came in at $64.0 million, up 435.29% from the prior year.
• Profit After Tax climbed to $38.3 million in Q1 2026, from $29.3 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of $48.4 million in Q3 2025 to a low of -$19.6 million in Q3 2024.
• A 5-year average of $3.9 million and a median of -$3.2 million in 2023 frame the typical range for Profit After Tax.
• Annual changes were most pronounced in 2024 — Profit After Tax soared 871.52% — and 2025, when it slumped 597.53%.
• Tracing ORMP's Profit After Tax over 5 years: stood at -$12.3 million in 2022, then jumped by 205.25% to $12.9 million in 2023, then tumbled by 179.07% to -$10.2 million in 2024, then jumped by 387.41% to $29.3 million in 2025, then jumped by 30.69% to $38.3 million in 2026.
• The last three Profit After Tax figures came in at $38.3 million (Q1 2026), $29.3 million (Q4 2025), and $48.4 million (Q3 2025), per Business Quant data.